Physician profile
Gregory M Rucker
NPI 1073510905
$1,186.71
in general payments reported to CMS, 2019-2025
16 companies · $83.17 in 2025
The $83.17 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $168 · 2021: $201 · 2022: $206 · 2023: $229 · 2024: $194 · 2025: $83.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $489.66 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $173.29 | 2020-2025 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.38 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $74.59 | 2022-2024 | |
| Astellas Pharma US INC | $65.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.86 | 2022 | |
| Merck Sharp & Dohme LLC | $42.04 | 2019-2023 | Verquvo, Belsomra, Steglujan |
| Abbvie INC. | $39.82 | 2021-2023 | Vraylar |
| Sanofi-Aventis U.S. LLC | $19.36 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $19.16 | 2023 | Farxiga |
| Sumitomo Pharma America, INC. | $18.81 | 2025 | Gemtesa |
| Abbott Laboratories | $18.46 | 2022 | |
| Avanir Pharmaceuticals, INC. | $18.26 | 2020 | |
| Esperion Therapeutics, INC. | $17.28 | 2021 | |
| Hikma Pharmaceuticals USA | $15.98 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $14.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Rucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.